Related Experiment Video

Updated: Aug 21, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Intestinal microbiota in the treatment of metabolically associated fatty liver disease

Ji-Shuai Wang1, Jin-Chun Liu2

  • 1Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.

World Journal of Clinical Cases
|November 17, 2022
PubMed

Insights

Metabolically associated fatty liver disease (MAFLD), linked to metabolic syndrome, lacks effective treatments. This review explores how gut microbiota imbalances impact MAFLD and discusses emerging gut-liver axis therapies.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Microbiology

Background:

  • Metabolically associated fatty liver disease (MAFLD) is a prevalent hepatic manifestation of metabolic syndrome.
  • The increasing incidence of MAFLD highlights the urgent need for effective therapeutic strategies.
  • Emerging evidence suggests a significant role for the intestinal microbiota in the pathogenesis of liver diseases, including MAFLD.

Purpose of the Study:

  • To review the current understanding of the intestinal microbiota's composition and characteristics in MAFLD.
  • To explore the therapeutic perspectives targeting the gut-liver axis for MAFLD treatment.
  • To synthesize recent research on the gut-liver axis in the context of MAFLD.

Main Methods:

  • Comprehensive literature review of studies investigating the gut-liver axis and MAFLD.
  • Analysis of research on intestinal microbiota alterations in MAFLD patients.
  • Evaluation of emerging therapeutic strategies targeting gut microbiota and the gut-liver axis.

Main Results:

  • Dysbiosis of the intestinal microbiota contributes to increased intestinal permeability.
  • Increased intestinal permeability leads to elevated liver exposure to adipokines, exacerbating MAFLD.
  • The gut-liver axis presents a promising target for novel MAFLD therapies.

Conclusions:

  • The intestinal microbiota plays a critical role in the development and progression of MAFLD.
  • Targeting the gut-liver axis offers a potential therapeutic avenue for MAFLD.
  • Further research into gut-targeted therapies is warranted for effective MAFLD management.
Keywords:
AdipokinesGut-liver axisIntestinal microbiotaMetabolically associated fatty liver diseaseTherapy

More Related Videos

Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.3K
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.7K

Related Concept Videos

Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
566
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
31.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
390
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
141
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169